- Home
- BYSI vs OTLK Comparison
BYSI vs OTLK Comparison
Compare BYSI & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYSI | OTLK |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.0M | 92.8M |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BYSI | OTLK |
|---|---|---|
| Price | $2.12 | $1.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 591.5K | ★ 3.4M |
| Earning Date | 11-12-2025 | 12-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,505,322.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $342.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.98 | $0.79 |
| 52 Week High | $3.44 | $3.39 |
Technical Indicators
Market Signals| Indicator | BYSI | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 55.99 | 60.38 |
| Support Level | $1.89 | $1.51 |
| Resistance Level | $2.16 | $2.10 |
| Average True Range (ATR) | 0.19 | 0.16 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 47.54 | 74.19 |
Price Performance
Historical ComparisonAbout BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.